PPT-Therapeutics for Hemophilia A

June 2013 Roger L Lundblad PhD Consultant in Biotechnology Chapel Hill North Carolina httpwwwlundbladbiotechcom And Adjunct Professor Department of Pathology University of North Carolina Chapel Hill North Carolina. Soma . Mukherjee. SMU,Chemistry. 5. th. April’2011. Introduction : Protein & important structural features for therapeutics.. Development. Classification. Examples of Protein as targeted delivery device. (. H. aemophilia). By: Morgan Dirienzo. The Royal Disease. Alternate Names and Symptoms. Some alternate names for Hemophilia would be Haemorrhaphilia, or Von Willebrand disease. . The Symptoms for Hemophilia are…. Introduction/Overview. Introduction/Overview (cont). Importance of Prophylaxis, and Limitations on Its Application, in Hemophilia B. Key Unmet Need in Hemophilia B:. Reducing Patient Burden of Disease. By: Nam-Y7. Hemophilia was first recognized by the Jews, but not officially named even in the ancient times. . In the 2. nd. century AD, the Talmud, a Jewish collection of Rabbinical writings said that the boys did not have to be circumcised if two brothers died of the disease. In 1800s, it became known as the Royal Disease because many people of royal families died or got the disease. Queen Victoria got Hemophilia but she survived. Alexei, the heir apparent to the Russian royal family, suffered from Hemophilia. In 1950s, the first treatment to hemophilia appeared. It was in a type called “fresh frozen plasma”. Nowadays, we are marching towards a cure but there are two treatments. One is called “gene therapy” and the other is called “Recombinant therapy”. A treatment for hemophilia is replacing old blood clots with new ones.. Microbiome Therapeutics Market report published by Value Market Research is an in-depth analysis of the market covering its size, share, value, growth and current trends for the period of 2018-2025 based on the historical data. This research report delivers recent developments of major manufacturers with their respective market share. In addition, it also delivers detailed analysis of regional and country market. View More @ https://www.valuemarketresearch.com/report/microbiome-therapeutics-market Sex-linked inheritance; almost all patients male. Female carriers may have mild symptoms. Most bleeding into joints, muscles; mucosal and CNS bleeding uncommon. Severity inversely proportional to factor level. A new ambition of the World Federation of Hemophilia. WFH Guidelines for the Management of Hemophilia. All recommendations are consensus based.. Srivastava A et al. Haemophilia. 2020;26(Suppl 6):1–158. . WVNHF. Amber Tichnell, Executive Director. Hemophilia and other bleeding disorders. The human body is made up of several clotting factors – Factors 1 through 13 plus Von . Willebrand. Factor. A person can have deficiencies in any of these factors. Hemophilia A. Also known as Factor VIII Deficiency is the most common type of hemophilia. It is a disorder of your blood-clotting system. Clotting is the process which your blood changes from a liquid to a solid state. Andrew J. . Costandi. , MD, MMM . Children’s Hospital Los Angeles. USC Keck School of Medicine. Faculty Disclosures. None. Learning Objectives. Upon completion of this activity, participants will be able to:. Veena Choubey, Rena Malik, and Luis Carlos Zapata Genetics Hemophilia is an X-linked recessive disorder that exists in two forms, hemophilia A and hemophilia B. Hemophilia A is characterized specif Mukherjee. SMU,Chemistry. 5. th. April’2011. Introduction : Protein & important structural features for therapeutics.. Development. Classification. Examples of Protein as targeted delivery device. Dr. S. Parthasarathy . MD., DA., DNB, MD (. Acu. ), . Dip. Diab.DCA, Dip. Software statistics . PhD (. physio. ). . Mahatma . gandhi. medical college and research institute, . puducherry. , India. Alfonso Iorio, MD PhD. McMaster University, Canada. Alfonso Iorio. MD, PhD, FRCPC. Professor of Medicine. McMaster University. Disclosures. McMaster University has received research, consultancy and educational funding for Population PK projects from Bayer, .